Abstract 1419P
Background
Brain metastases (BM) are a frequent complication in patients with non-small lung cancer (NSCLC). Treating BM is challenging as the blood-brain barrier can limit intracranial drug delivery. Data from different trials suggest that antibody-drug conjugates (ADC) can have clinically relevant intracranial activity. This study aims to characterize the gene expression of ADC targets in NSCLC-BM to guide treatment decisions.
Methods
Gene expression data from 125 BM resected from patients with NSCLC were obtained from 3 public datasets. Gene expression of 14 ADC targets (ERBB2, ERBB3, TACSTD2, MET, GPNMB, PTK7, MSLN, CD276, TF, AXL, EGFR, SLC34A2, CEACAM5 and ROR2) was evaluated to identify those consistently expressed across the cohorts. Additionally, hierarchical clustering was used to stratify NSCLC-BM, in each dataset separately, based on the combined relative gene expression of the common 25% most variable genes: MSLN, CEACAM5 and SLC34A2. Furthermore, association between clusters and clinical covariates was assessed for one of the datasets with available data (N=63).
Results
Gene expression evaluation showed that TACSTD2 (Trop-2) was ubiquitously highly expressed across datasets, suggesting that TACSTD2 could be a promising ADC target for NSCLC-BM. Contrarily, ROR2 showed consistently lower expression and would probably not be a good candidate in NSCLC-BM. Transcriptional patterns from the 3 most variable ADC targets (MSLN, CEACAM5, and SLC34A2) yielded common subgroups in all datasets defined by the following expression levels (respectively): High/High/High, Low/High/High, High/Low/Low. These groups did not correlate with clinical covariates.
Conclusions
Gene expression evaluation of ADC targets in NSCLC-BM resulted in the identification of TACSTD2 expression across all datasets. TACSTD2 might be a promising ADC target for patients with NSCLC with BM. Further validation is warranted in terms of protein expression. Our results underscore the potential value of gene expression profiling to identify new targets and improve patient selection in the context of NSCLC-BM ADC therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Instituto de Salud Carlos III (CM22/00035).
Disclosure
E. Nadal: Financial Interests, Personal, Advisory Board: Roche, Bristol Myers Squibb, Merck Sharp Dohme, Boehringer Ingelheim, Lilly, Janssen, Pfizer, Merck Serono, Daiichi Sankyo, AstraZeneca, Takeda, Amgen, Sanofi, Qiagen, Janssen; Financial Interests, Personal, Invited Speaker: Roche, Bristol Myers Squibb, Merck Sharp Dohme, Boehringer Ingelheim, Lilly, Pfizer, Sanofi, AstraZeneca, Takeda, Amgen, Qiagen, Janssen; Financial Interests, Personal and Institutional, Funding, Clinical trial funded by Roche: Roche; Financial Interests, Personal and Institutional, Funding, BMS funded a clinical trial: Bristol Myers Squibb; Financial Interests, Personal and Institutional, Funding, Merck Serono funded a clinical trial: Merck Serono; Non-Financial Interests, Advisory Role: Pfizer, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
1368P - LUMINATE 102: A real-world study on biomarker testing rates among patients with non-small cell lung cancer (NSCLC) across lines of therapy
Presenter: Charu Aggarwal
Session: Poster session 20
1369P - BrigAlec study: Focus on alectinib efficacy after brigatinib exposure in BrigALK2 study (GFPC 02-2019)
Presenter: Renaud Descourt
Session: Poster session 20
1370P - Efficacy and safety of ensartinib in ALK-positive non-small cell lung cancer patients with brain metastases: A multicenter, open-label, single-arm, phase II study
Presenter: Jianhua Chang
Session: Poster session 20
1371P - First-line alectinib vs. brigatinib in advanced metastatic NSCLC with ALK rearrangement: Real-world data
Presenter: Young Kyung Jeon
Session: Poster session 20
1372P - Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial
Presenter: Ben Solomon
Session: Poster session 20
1373P - Efficacy and safety of taletrectinib in patients (Pts) with ROS1+ non-small cell lung cancer (NSCLC): Interim analysis of global TRUST-II study
Presenter: Maurice Pérol
Session: Poster session 20
1374P - Survival and therapy analysis of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients
Presenter: Moritz Glaser
Session: Poster session 20
1375P - Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data
Presenter: Frans Opdam
Session: Poster session 20
1377P - Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity
Presenter: Xiuning Le
Session: Poster session 20
1378P - Efficacy and safety of tunlametinib (HL-085) combined with vemurafenib in patients with advanced BRAF V600-mutated solid tumors: A multicenter, phase I study
Presenter: Yuan-Kai Shi
Session: Poster session 20